Page 25 - Sun Pharma

Sun Pharma to test two drugs for treatment of Covid-19, stock up 3.5%

At present there are three clinical trials underway to test nafamostat in Covid19 patients around the world

Sun Pharma to test pancreatitis drug in Covid-19 patients in India

Sun Pharma it has initiated manufacturing of the active pharmaceutical ingredient and the finished product of the drug using technology from its unit, Pola Pharma Japan.

Corona warriors for markets: Ambani, Adani stocks rise most since lockdown

The Bajaj group is the only one on the list of 12 conglomerates to be down - 1 per cent - since the lockdown came into effect, thanks to the hammering of stocks of non-banking financial companies.

Specialty products segment key to Sun Pharma's growth prospects

Pricing pressure in US, lockdown may dent near-term prospects

Sun Pharma up nearly 2% post-March quarter nos; here's what brokerages say

Net profit, too, saw a 37 per cent YoY fall to Rs 399.8 crore, against estimates of Rs 950-1,000 crore.

Sun Pharma's Q4 pre-tax profit down 17% at Rs 577 cr on multiple one-offs

Revenues in the US market, its largest geography, came in at $375 million down 15 per cent, though the year ago period had a high base due to a one-time contribution of specialty products

Sun Pharma Q4 profit declines 37% to Rs 399 cr on one-time exceptional loss

The company had posted a net profit of Rs 635.88 crore in the same period previous fiscal, Sun Pharma said in a BSE filing

Market Ahead, May 27: All you need to know before the opening bell

Today, a total of 21 companies, including Dabur India, Sun Pharma, and United Spirits are scheduled to announce their results.

Covid-19 crisis prompts India to look for global partners in health care

Medical devices industry has potential to attract Rs 70,000 crore in 5 years

Strength in Nifty only above 9,300 levels: Gaurav Garg of CapitalVia

Technical Calls by Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor

Broad-based rally possible once Nifty crosses 9,450: Angel Broking

At present, traders are advised to stay light and should ideally continue focusing on individual stocks

Two stocks that Vaishali Parekh of Prabhudas Lilladher is bullish on

For HUL's stock, the bias has improved a lot and the stock has the potential to rise further

Top stock picks by CapitalVia Global Research: Buy Sun Pharma, Lupin

Technical Calls by Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor

Lockdown 3.0: Pharma hubs take extra precaution to tame Covid-19 outbreak

Recently, while 26 workers at Cadila Pharmaceuticals facility in Ahmedabad tested positive for Covid-19, one person at Sun Pharma's Halol plant tested positive.

Pharma shares rally; Alembic, Sun Pharma, Laurus Labs hit 52-wk highs

Strides Pharma Science, Alkem Laboratories, Ajanta Pharma, Lupin, Ipca Laboratories, Jubilant Life Sciences and FDC were up in the range of 5 per cent to 10 per cent on the BSE

Sun Pharma regains Rs 1 trillion m-cap after surging 38% in four days

The stock was trading close to its 52-week high of Rs 480, touched on April 10, 2019

Sun Pharma's product approvals at risk as USFDA labels Halol plant as OAI

Earlier in December, the plant had been issued Form 483 by USFDA with eight observations

Top 10 biz headlines: Carnage on D-Street, Sun Pharma mulls share buyback

From RBI offering $2-bn swaps to Tata Sons buying group firms' shares, here are the top 10 business headlines for the day

Share buyback plan fails to lift Sun Pharma; stock hits over 7-year low

The drugmaker announced that its board will meet on Tuesday, March 17, 2020 to consider the buyback of company's shares

Sun Pharma board to consider buyback of shares next week

Analyst say more promoters likely to seek ways to cushion share price